|1.||Kashyap, Moti L: 23 articles (09/2015 - 03/2002)|
|2.||Lai, Eseng: 17 articles (08/2012 - 04/2006)|
|3.||Offermanns, Stefan: 15 articles (04/2015 - 03/2003)|
|4.||Kirkland, James B: 14 articles (05/2012 - 01/2002)|
|5.||Waters, M Gerard: 13 articles (01/2013 - 07/2005)|
|6.||Kamanna, Vaijinath S: 12 articles (09/2015 - 01/2003)|
|7.||Maccubbin, Darbie: 12 articles (05/2015 - 11/2008)|
|8.||Bays, Harold E: 12 articles (01/2015 - 03/2002)|
|9.||Paolini, John F: 12 articles (08/2012 - 07/2007)|
|10.||Ballantyne, Christie M: 12 articles (07/2011 - 11/2002)|
08/01/2007 - "Niacin remains the safest and most effective agent for raising HDL-C and is a logical choice to target atherogenic dyslipidemia. "
02/15/2002 - "These results demonstrate that combination statin-fibrate and statin-niacin regimens are safe and effective in managing dyslipidemias in most patients at risk for cardiovascular events who are inadequately treated with one of these agents alone."
02/01/2007 - "Niacin is an effective treatment for dyslipidemia due to its favorable effects on multiple lipid parameters. "
07/01/2004 - "This meta-analysis confirms that women respond as well as men, and possibly slightly better, to treatment with extended-release niacin and that it is a safe and effective treatment option for women with dyslipidemia."
10/01/2011 - "Nicotinic acid is an effective treatment for dyslipidemia. "
09/01/2002 - "Niacin ER has a delivery system allowing absorption rates intermediate to that of niacin IR and SR. As a result, niacin ER achieves the efficacy of niacin IR with a reduced incidence of flushing and without the hepatic effects seen with niacin SR. The pharmacist should be familiar with the differences among and the advantages and disadvantages of each formulation to educate patients and help them achieve the optimal therapeutic benefit of niacin while minimizing adverse effects."
12/13/2007 - "Compound 2i exhibited good in vivo antilipolytic efficacy while providing a significantly improved therapeutic index over vasodilation (flushing) with respect to niacin in the mouse model."
01/12/2012 - "Compound 33 had no overt signs of flushing at doses up to 10 mg/kg with an improved therapeutic window to flushing as compared to nicotinic acid. "
01/01/2011 - "Niacin is particularly effective in achieving normalization of HDL-C but is clinically underutilized due to the side effect of cutaneous flushing. "
08/01/2010 - "These data will help to guide new efficient approaches to mitigate nicotinic acid-induced flushing and may help to exploit the potential antipsoriatic effects of GPR109A agonists in the skin."
06/01/2013 - "Better understanding of niacin's actions on multiple tissues and targets may be helpful in designing combination therapy and new treatment strategies for atherosclerosis."
01/01/2011 - "Niacin has been used for more than 50 years in the management of atherosclerosis and is associated with improved patient outcomes. "
01/01/2015 - "BACKGROUND Niacin is a broad-spectrum lipid-regulating drug used for the clinical therapy of atherosclerosis; however, the mechanisms by which niacin ameliorates atherosclerosis are not clear. "
12/01/2011 - "There has been renewed interest in nicotinic acid owing to the need for improved prevention of atherosclerosis in patients already taking statins. "
12/01/1978 - "Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds."
09/01/1989 - "Nicotinic acid has a proven efficacy in the treatment of hypercholesterolemia. "
01/01/1992 - "Wax-matrix niacin (Endur-acin) was shown to be effective and well tolerated for the pharmacological treatment of hypercholesterolemia. "
09/15/1998 - "We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. "
09/01/1998 - "This study compared the efficacy and safety of a once-a-night, time-release niacin formulation, Niaspan (Kos Pharmaceuticals, Miami Lakes, FL), with plain niacin and placebo for the treatment of primary hypercholesterolemia. "
12/01/1963 - "A LONG TERM STUDY OF THE EFFECT OF NICOTINIC ACID MEDICATION ON HYPERCHOLESTEREMIA."
09/01/2000 - "High-dose niacin has versatile and substantial efficacy for the treatment of hyperlipidemias, but its utility is compromised by various side effects, the most serious of which is liver damage. "
09/01/1998 - "Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia."
01/01/2015 - "Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?"
12/01/2014 - "In summary, this study provides basis and reference for extracting new nicotinic acid receptor agonists from traditional Chinese medicines and improving the medication status of hyperlipidemia."
06/01/1998 - "The study involved a group of 30 patients with hyperlipidemia of type II. The concentration of nicotinic acid in serum was determined using capillary electrophoresis. "
|1.||Niacin (Nicotinic Acid)
|5.||Fibric Acids (Fibrates)
|1.||Drug Therapy (Chemotherapy)
|2.||Renal Dialysis (Hemodialysis)
|5.||Estrogen Replacement Therapy